[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NZ630831A - Compositions and methods for administration of vaccines against dengue virus - Google Patents

Compositions and methods for administration of vaccines against dengue virus

Info

Publication number
NZ630831A
NZ630831A NZ630831A NZ63083113A NZ630831A NZ 630831 A NZ630831 A NZ 630831A NZ 630831 A NZ630831 A NZ 630831A NZ 63083113 A NZ63083113 A NZ 63083113A NZ 630831 A NZ630831 A NZ 630831A
Authority
NZ
New Zealand
Prior art keywords
dengue virus
administration
compositions
methods
vaccines against
Prior art date
Application number
NZ630831A
Inventor
Dan T Stinchcomb
Jorge E Osorio
Charalambos D Partidos
Joseph N Brewoo
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/492,884 external-priority patent/US8968996B2/en
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of NZ630831A publication Critical patent/NZ630831A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed is a method for rapid induction of neutralizing antibodies in a subject against three or more dengue virus serotypes, comprising, subcutaneous administration of two or more doses of a single formulation of a live, attenuated dengue virus vaccine to a subject at two or more anatomical locations on the same day.
NZ630831A 2012-06-10 2013-06-10 Compositions and methods for administration of vaccines against dengue virus NZ630831A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/492,884 US8968996B2 (en) 2009-06-01 2012-06-10 Compositions and methods for rapid immunization against dengue virus
PCT/US2013/045041 WO2013188315A1 (en) 2012-06-10 2013-06-10 Compositions and methods for administration of vaccines against dengue virus

Publications (1)

Publication Number Publication Date
NZ630831A true NZ630831A (en) 2019-02-22

Family

ID=48652375

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630831A NZ630831A (en) 2012-06-10 2013-06-10 Compositions and methods for administration of vaccines against dengue virus

Country Status (6)

Country Link
EP (1) EP2858668A1 (en)
JP (2) JP2015520196A (en)
CA (1) CA2915027A1 (en)
NZ (1) NZ630831A (en)
TW (1) TW201402143A (en)
WO (1) WO2013188315A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9878031B2 (en) 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
CN113637086B (en) 2013-03-15 2024-10-11 武田疫苗股份有限公司 Compositions and methods for dengue virus chimeric constructs in vaccines
CA2991212A1 (en) 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
JP2018535191A (en) 2015-09-26 2018-11-29 プライムヴァックス イミュノ−オンコロジー，インク． Compositions and methods for producing dendritic cells
SG10201913383RA (en) * 2016-04-13 2020-03-30 Takeda Vaccines Inc Compositions and methods of vaccination against dengue virus in children and young adults
TWI625393B (en) * 2016-11-15 2018-06-01 國立清華大學 A vaccine kit against multiple dengue virus serotypes and preparation and application thereof
CN110139671A (en) 2016-11-16 2019-08-16 普莱瓦克斯免疫肿瘤学公司 Combination immunotherapy for treating cancer
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
BR112021003962A2 (en) 2018-09-05 2021-05-25 Takeda Vaccines, Inc. unit dose of dengue vaccine and its administration
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110196B2 (en) * 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
FR2906724B1 (en) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
WO2010141386A1 (en) * 2009-06-01 2010-12-09 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus

Also Published As

Publication number Publication date
JP2018090618A (en) 2018-06-14
JP2015520196A (en) 2015-07-16
WO2013188315A1 (en) 2013-12-19
CA2915027A1 (en) 2013-12-19
EP2858668A1 (en) 2015-04-15
TW201402143A (en) 2014-01-16

Similar Documents

Publication Publication Date Title
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
MX2018007627A (en) Zika virus vaccine.
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
MX2012009581A (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease.
MX2015010305A (en) Combination vaccine for respiratory syncytial virus and influenza.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
EA202090699A2 (en) COMPOSITIONS CONTAINING A BUFFER, VACCINES THAT CONTAIN COMPOSITIONS CONTAINING A BUFFER, AND THEIR APPLICATION
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
MX346596B (en) Immunostimulatory oligodeoxynucleotides.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
PH12015501333A1 (en) Method of making a mycoplasma vaccine
MX2021013109A (en) Process for preparing an attenuated tetravalent dengue vaccine.
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MX2022013912A (en) Novel methods for inducing an immune response.
MX2022000746A (en) Dimethyl fumarate and vaccination regimens.
MX2015017257A (en) Compositions and methods of immunizing against c. difficile.
MX2016007224A (en) Vaccine against porcine circo virus type 2.
MX2016002823A (en) Methods and compositions for viral vectored vaccines.
GB2515222A (en) Use of flagellin as a vaccine
ES2503516R1 (en) IMMUNOGENIC COMPLEX FOR VACCINATION AND METHOD OF OBTAINING
MX350718B (en) Equine rhinitis vaccine.
WO2013173256A3 (en) New and improved influenza vaccines
IN2013DE02372A (en)
UA69683U (en) Method for treatment of patients with steatohepatitis

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed